Addressing Segregation of a Low-Dosage Direct Blend - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Addressing Segregation of a Low-Dosage Direct Blend
The authors modified equipment and the manufacturing process to re-establish content uniformity among tablets.

Pharmaceutical Technology
Volume 35, Issue 2, pp. 78-82

Results and conclusion

Figure 4: Stratified tablet content-uniformity data for (a) demonstration batch #1 with segregation and (b) demonstration batch #2 after process and equipment modifications. (ALL FIGURES ARE COURTESY OF THE AUTHORS)
The process and equipment modifications implemented for the second demonstration batch were successful in reducing the CU variation and alleviating the upward CU trend that was observed at the end of compression in the first demonstration batch, as shown in Figure 4. The CU data for the second demonstration batch showed minimal variation (RSD = 0.9%, n = 60 samples) and met the FDA draft guidance specifications. The successful validation of the commercial process further demonstrated the robustness of these modifications.


The authors thank their colleagues Prasad Challapalli, senior scientist at Patheon; Jacques Mowrer, associate director of analytical chemistry, and Alicia Ng, analytical chemist, at Transcept; and Mary Thomas, former manufacturing-process engineer at Patheon for their collaboration on this project.

Nipun Davar is a vice-president of pharmaceutical sciences at Transcept Pharmaceuticals. Thomas Baxter is a senior consultant at Jenike & Johanson. Pauly Kavalakatt is a senior scientist of formulation development, and Sangita Ghosh* is an associate director of product development, both at Transcept Pharmaceuticals, 1003 W. Cutting Blvd., Pt. Richmond, CA, 94804, tel. 510.215.3500,
. Herbert Schock is a technical manager of commercial operations at Patheon Pharmaceuticals

*To whom all correspondence should be addressed.

Submitted: Aug. 19, 2010. Accepted: Nov. 8, 2010.


1. FDA, Powder Blends and Finished Dosage Units—Stratified In-Process Dosage Unit Sampling and Assessment (Rockville, MD, Oct. 2003).

2. FDA, Powder Blends and Finished Dosage Units—Stratified In-Process Dosage Unit Sampling and Assessment, Revised Attachments (Rockville, MD, Nov. 2003).

3. J.K. Prescott and T.P. Garcia, Pharm. Technol. 25 (3), 68–79 (2001).

4. J.K. Prescott, and R.J. Hossfeld, Pharm. Technol. 18 (6), 99–114 (1994).

5. J.K. Prescott et al., Pharm. Technol. 30 (12), 54–64 (2006).

6. J.K. Prescott and R.A. Barnum, Pharm. Technol. 24 (10), 60–84 (2000).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here